The stock market has been holding up remarkably well, but why? Against the backdrop of weak second quarter earnings results, investors are piling …
Written by Daniel Cohen and Scott Matusow Lately, many early stage developmental biotech companies have been going on some seriously epic runs. Karuna …
Curis, Inc. (NASDAQ:CRIS) announced that it has exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option …
Curis, Inc. (NASDAQ:CRIS) announced that on January 1, 2017, the independent Compensation Committee of the Board of Directors of Curis approved the grant …
Curis, Inc. (NASDAQ:CRIS) announced the appointment of Lori A.
Curis, Inc. (NASDAQ:CRIS) announced the expansion of its pipeline with CA-327, an oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and …
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today …
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced …
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human …
